A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Clinical trial NCT01339923 · COMPLETED

Trial details

NCT number: NCT01339923
Sponsor: Novartis Vaccines
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Meningococcal Disease Meningococcal Meningitis

Start date: 2011-04-01
Primary completion: 2014-01-01
Enrollment: 1409

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.